This might be very interesting! Analyst puts it on the line $23 PT for a $1 stk!! 
Roth 'struggles to understand' why Syros trades at $1.15 with 3 readouts ahead 13:39 SYRS Roth Capital analyst Zegbeh Jallah notes Syros hosted its Q4 earnings and business update call, with the company reaffirming data readouts from the Phase 2 study of Tamibarotene in ND-AML in the second half of 2022, Phase 3-dose-confirmation study for SY-2101 in APL in mid-2022, and the Phase-1 SY-5609 combo study in pancreatic cancer in the second half of 2022, with plans to initiate a Phase 1 study of SY-5609 in heme malignancies during the second half of 2022. With three readouts ahead, Jallah struggles to understand why Syros trades at $1.15. The analyst reiterates a Buy rating on the shares with a price target of $23.
Roth 'struggles to understand' why Syros trades at $1.15 with 3 readouts ahead 13:39 SYRS Roth Capital analyst Zegbeh Jallah notes Syros hosted its Q4 earnings and business update call, with the company reaffirming data readouts from the Phase 2 study of Tamibarotene in ND-AML in the second half of 2022, Phase 3-dose-confirmation study for SY-2101 in APL in mid-2022, and the Phase-1 SY-5609 combo study in pancreatic cancer in the second half of 2022, with plans to initiate a Phase 1 study of SY-5609 in heme malignancies during the second half of 2022. With three readouts ahead, Jallah struggles to understand why Syros trades at $1.15. The analyst reiterates a Buy rating on the shares with a price target of $23.
That's the way we roll folks.